Long before cannabis became a political flashpoint or a wellness industry talking point, it was simply part of the fabric of European life — woven into the soil, the kitchen, the midwife’s bag, and the parish gossip. Hemp festivities were common across the continent well before Columbus set sail. Farmers sowed hempseed on days associated with tall saints, hoping that some sympathetic magic might coax the stalks skyward. Peasants danced through hemp fields at harvest time. Young women in Ukraine and England tucked hempseed into their pockets as love charms. At Slavic weddings, brides were showered with it like confetti. The French kept a phrase for good fortune that translated, literally, as “to have hemp in your pocket.” This was not a plant on the margins — it was one that sat at the center of rural European existence, carrying meanings practical, spiritual, and medicinal all at once.
What it was not, in any meaningful sense, was psychoactive. The varieties of hemp that thrived in northern Europe’s cooler growing conditions carried low concentrations of tetrahydrocannabinol — THC, the compound responsible for the intoxicating effects associated with cannabis. The smoldering vapors that peasant folklore credited with disease-repelling properties were not getting anyone high. But this is precisely what makes the depth of European hemp culture so instructive: the continent’s traditions implicitly understood something that Western pharmacology would take centuries to formally articulate — that THC is not the whole story. Fiber hemp, low in psychoactive potency, was still considered a powerful healing plant because, as modern science has since confirmed, cannabis contains a wide range of therapeutic compounds beyond THC that act on the body in meaningful ways.
The medicinal applications were specific and practical. Hemp served Germanic healers as a treatment for fever, burns, headaches, and infected wounds — the latter dressed with a paste of hemp flowers, wax, and olive oil. Midwives placed sprigs of the plant over the stomachs and ankles of pregnant women to prevent convulsions during labor. The twelfth-century German mystic and folk healer Hildegard von Bingen wrote about hemp — hanaf, as she called it — in her botanical compendium Physica. A century’s worth of German herbalists followed her lead, culminating in the sixteenth-century Kreuterbuch of Tabernaemontanus, a Basel physician whose massive herbal encyclopedia contains the first written European reference to medicinal hemp smoke.
That the Church took a dim view of all this is hardly surprising. In 1484, Pope Innocent VIII outlawed hemp by papal decree, linking it to witches’ unguents and the pre-Christian ritual practices the Church had spent centuries trying to stamp out. Rural communities continued using it anyway, as rural communities tend to do with things that work — they simply stopped talking about it openly. François Rabelais, the irreverent French Renaissance physician and satirist, buried references to hemp deep in the allegorical vegetation of Gargantua and Pantagruel, where “the good herb pantagruelion” provided medicine, rope, sails, and nooses in equal measure. It was still too obvious: Rome banned the books. A generation later, William Shakespeare may have been doing something similar with his veiled allusions to “the noted weed” and “compounds strange” — though whether the Bard himself was a participant or merely an observer remains one of literary history’s more enjoyable open questions. In 2001, forensic scientists analyzed clay pipe fragments excavated near Shakespeare’s Stratford-upon-Avon home and found several that tested positive for hemp. They also found tobacco — and, intriguingly, traces of coca leaf from Peru — which raises the rather entertaining possibility that the fragments were evidence not of Shakespearean self-medication but of adulterated street product, early modern dealers cutting their tobacco with whatever came to hand.
The Science Catches Up
The shift from folk remedy to formal medicine required a mediating figure, and that figure arrived in the form of William Brooke O’Shaughnessy — an Irish physician of formidable range who, while serving with the British East India Company in the 1830s, essentially introduced cannabis to Western clinical practice. O’Shaughnessy was not a narrow specialist. He oversaw the construction of the first telegraph system in colonial India, a 3,500-mile project that earned him a knighthood from Queen Victoria. He taught chemistry, practiced surgery at the Medical College of Calcutta, and brought to the question of “gunjah” — his transliteration of the Indian term — the curiosity of a man accustomed to solving difficult problems from first principles.
What O’Shaughnessy found across India, Nepal, Afghanistan, and Persia was a plant already embedded in centuries of Ayurvedic therapeutic tradition. He watched local healers blend ganja resin with ghee — clarified butter — into a nerve tonic. He observed four and five people sharing a hookah in social and ritual settings. He sampled the tincture himself before administering it to patients, a standard of personal diligence that feels almost quaint in the age of placebo-controlled trials. His clinical experiments covered rabies, cholera, tetanus, epilepsy, and rheumatism — conditions that nineteenth-century medicine had few reliable tools to address — and the forty-page monograph he published in 1842 became the first modern medical article on cannabis to appear in a British scientific journal. Its reception on both sides of the Atlantic was, putting it generously, attentive.
The effects O’Shaughnessy catalogued — “perpetual giggling,” “ravenous appetite,” “a sensation of ascending,” “mental exultation” — will be recognizable to anyone who has encountered a well-cultivated indica on a Friday evening. More clinically significant was his identification of cannabis as a painkiller, a muscle relaxant, and what he called “an anti-convulsive remedy of the greatest value.” He noted also that a retiring young Scottish student, after swallowing “the spiritous tincture,” had proceeded to hold forth on scientific, religious, and political topics with the commanding authority of a rajah — behavior O’Shaughnessy likened to the trance oracles at Delphi, and which he found “difficult to imagine a scene more interesting.”
The most consequential observation in O’Shaughnessy’s paper, however, was not about any single effect but about the plant’s relationship with dosage. He noted that hemp in small doses “possessed an extraordinary power of stimulating the digestive organs and exciting the cerebral system,” while larger doses produced the opposite — insensibility, sedation, and in cases of excessive administration, something he described as “a peculiar form of delirium.” His concluding clinical recommendation was unambiguous: prefer small doses, to excite rather than narcotize the patient. This was, in modern pharmacological terms, a description of the biphasic effect — the principle that a substance’s therapeutic action at low doses can be reversed entirely at high ones. Cannabis does not follow the allopathic logic that would come to govern mainstream Western medicine, the assumption that if a little of something works, more will work better. It follows its own logic, one that aligns more closely with homeopathic thinking — a framework that O’Shaughnessy credited to Samuel Hahnemann, who had himself recommended micro doses of cannabis for nervous disorders. The less-is-more dynamic intrinsic to cannabis as a medicine remains among the most persistently misunderstood aspects of the plant, and O’Shaughnessy identified it almost two centuries ago.
The Apothecary’s Shelf
The translation of O’Shaughnessy’s findings into commercial practice was rapid. He returned to England in 1842 carrying Indian hemp, a portion of which he gave to the London pharmacist Peter Squire, who developed an alcohol-based tincture under O’Shaughnessy’s supervision. “Squire’s Extract” entered European and American medical practice almost immediately, prescribed for nausea, epilepsy, painful spasms, and the agonies of delirium tremens — the severe withdrawal syndrome associated with alcohol dependence. The U.S. Pharmacopeia added Indian hemp to its official listings in 1854, noting the already-recognized problem of variable potency across different preparations. By the close of the nineteenth century, more than a hundred papers in medical and scientific journals had documented its therapeutic applications.
What followed was something close to a mainstream pharmaceutical moment. Eli Lilly, Parke-Davis, and Squibb — the forerunners of the modern pharmaceutical industry — were all selling cannabis preparations alongside a chaotic marketplace of over-the-counter patent medicines that combined Indian hemp with cocaine, morphine, and whatever else seemed commercially promising. Grimault & Sons was marketing ready-rolled cannabis cigarettes as an asthma treatment. Hemp was a standard ingredient in muscle ointments, poultices, and mustard plasters across the United States. Cannabis was not a fringe remedy. It was infrastructure.
Sir William Osler, frequently cited as the founder of modern medicine, endorsed it as the most effective treatment available for migraine headaches — noting not only its analgesic properties but its capacity to suppress the nausea and vomiting that accompany a severe attack. Sir John Russell Reynolds, physician to Queen Victoria herself, prescribed hemp tincture for the Queen’s menstrual pain and recommended it for insomnia. “When pure and administered carefully,” Reynolds wrote, “it is one of the most valuable medicines we possess.” There is a particular historical irony in the fact that a substance now regarded in many jurisdictions as a Schedule I drug with no accepted medical use was once standard care in the households of European royalty.
The history of cannabis medicine is not, as its opponents have sometimes characterized it, a recent invention of the legalization movement or the wishful thinking of recreational users searching for respectability. It is a documented record stretching from Hildegard von Bingen’s twelfth-century herbal notes to the Victorian consulting room, from Ayurvedic nerve tonics mixed with clarified butter to the shelves of Eli Lilly. The plant was suppressed not because the evidence failed it but because the political and industrial forces that came to dominate twentieth-century medicine decided it should be. Understanding that history does not resolve every contemporary question about cannabis therapeutics — dosage, standardization, and the challenges of clinical research remain genuinely complex — but it does clarify what was lost, and why recovering it has proven so difficult. Cannabis was not discovered as medicine. It was rediscovered, imperfectly, after a long and largely unnecessary interruption.